3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
211
Recurrence
27
Neoplasms, Plasma Cell
15
Neoplasms
13
Immunoglobulin Light-chain Amyloidosis
13
Leukemia, Myeloid, Acute
9
Lymphoma, Non-Hodgkin
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Smoldering Multiple Myeloma
5
Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasm, Residual
4
Hematologic Neoplasms
4
Plasmacytoma
3
Paraproteinemias
3
Myelodysplastic Syndromes
3
Leukemia, Plasma Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Hematologic Diseases
3
Carcinoma, Non-Small-Cell Lung
3
Amyloidosis
3
Waldenstrom Macroglobulinemia
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Plasmablastic Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Disease
2
Corneal Diseases
2
Blood Protein Disorders
2
Interventions
fludarabine
3
Cyclophosphamide
3
thymoglobulin
1
prednylidene
1
ofatumumab
1
deltacortene
1
daratumumab
1
carmustine, poliferprosan 20 drug combination
1
Prednisone
1
Peripheral Blood Stem Cell Transplantation
1
Mitoxantrone
1
Melphalan
1
Immunoglobulins, Intravenous
1
Etoposide
1
Cytarabine
1
Carmustine
1
Antilymphocyte Serum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Autoimmune Diseases of the Nervous System
×
daratumumab
×
Clear all
NCT06867991
2025-07-15
RADIA
The First People's Hospital of Changzhou
Phase 3
Recruiting
200 enrolled